Bispecific anti-axl and anti-pd-l1 antibodies and their use in therapy, in particular in tumor therapy

By developing bispecific antibodies that bind to AXL and PD-L1, promoting their internalization and degradation, the limitations of existing tumor treatment options and significant side effects have been addressed, resulting in more efficient and specific tumor treatment outcomes.

CN122161857APending Publication Date: 2026-06-05CELON PHARMA
View PDF 50 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
CELON PHARMA
Filing Date
2024-10-10
Publication Date
2026-06-05

AI Technical Summary

Technical Problem

The lack of existing technologies for bispecific constructs that can force the internalization and degradation of AXL and PD-L1 molecular targets by stimulating the immune system results in limited cancer treatment options and numerous side effects.

Method used

Develop bispecific antibodies containing antigen-binding domains or fragments thereof that specifically bind to AXL and PD-L1, promoting antigen internalization and degradation. Preferably, heavy chain antibody variable domains (VHH) and single chain variable fragments (scFv) are used, linked by amino acid linkers to form multivalent or multi-complementary antibodies.

Benefits of technology

It improves the effectiveness, specificity, and selectivity of cancer treatment, reduces side effects, simplifies production, lowers costs, and enhances the immune response, especially against cancer cells expressing AXL and PD-L1.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The present invention provides bispecific antibodies comprising one or more antigen binding domains that specifically bind to an AXL antigen and one or more antigen binding domains that specifically bind to a PD-L1 antigen, which binding to the AXL and / or PD-L1 antigen results in its internalization, and antigen binding fragments thereof that specifically bind to AXL and / or PD-L1. Also provided are nucleic acids encoding the bispecific antibodies or antigen binding fragments thereof, antibody-drug conjugates comprising the bispecific antibodies or antigen binding fragments thereof, and pharmaceutical compositions comprising the bispecific antibodies or antigen binding fragments thereof or the antibody-drug conjugates and a pharmaceutically acceptable excipient or carrier. Bispecific antibodies or conjugates or pharmaceutical compositions for use in the treatment of tumors, particularly malignant tumors, tumors that exhibit surface expression of AXL and / or PD-L1, are provided. Methods of treating or preventing tumors or metastases thereof and methods of stimulating an immune response comprising administration of the bispecific antibodies, fragments, conjugates or pharmaceutical compositions are also provided.
Need to check novelty before this filing date? Find Prior Art